PORTEC-4a: Molecular Profile-Based Adjuvant Treatment for High-Intermediate Risk Endometrial Cancer Last updated on Jun 8, 2026 Previous AtTEnd: Atezolizumab plus Chemotherapy for Advanced or Recurrent Endometrial Cancer Next EMPOWER-Cervical 1 (GOG-3016 / ENGOT-cx9): Cemiplimab vs. Chemotherapy in Recurrent/Metastatic Cervical Cancer
